Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding

Ju H. Kim; Donald F. Brophy; Keyur B. Shah

doi:10.1016/j.ccl.2018.06.006

Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding

Ju H. Kim, Donald F. Brophy, Keyur B. Shah

Houston Methodist

Research output: Contribution to journal › Review article

8 Scopus citations

Abstract

Continuous-flow (CF) left ventricular assist devices (LVADs) are a safe and durable therapeutic option for patients with advanced heart failure as a bridge to transplant or as destination therapy. Despite the remarkable technological advances in device design and increasing familiarity with the physiologic effects of CF, major complications such as gastrointestinal bleeding (GIB) continue to cause significant morbidity. The causes underlying CF-LVAD–related GIB are multifactorial. Accordingly, management strategies for CF-LVAD–related GIB encompass a wide range of therapeutic modalities. This article reviews the epidemiology, pathophysiology, risk factors, and treatment options for the management of this complex complication.

Original language	English (US)
Pages (from-to)	519-529
Number of pages	11
Journal	Cardiology Clinics
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.ccl.2018.06.006
State	Published - Nov 1 2018

Keywords

Angiodysplasia
Gastrointestinal bleed
Left ventricular assist device
Octreotide

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ccl.2018.06.006

Fingerprint Dive into the research topics of 'Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding'. Together they form a unique fingerprint.

Cite this

@article{0b3395855b654206b19ef6dc641ef7fe,

title = "Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding",

abstract = "Continuous-flow (CF) left ventricular assist devices (LVADs) are a safe and durable therapeutic option for patients with advanced heart failure as a bridge to transplant or as destination therapy. Despite the remarkable technological advances in device design and increasing familiarity with the physiologic effects of CF, major complications such as gastrointestinal bleeding (GIB) continue to cause significant morbidity. The causes underlying CF-LVAD–related GIB are multifactorial. Accordingly, management strategies for CF-LVAD–related GIB encompass a wide range of therapeutic modalities. This article reviews the epidemiology, pathophysiology, risk factors, and treatment options for the management of this complex complication.",

keywords = "Angiodysplasia, Gastrointestinal bleed, Left ventricular assist device, Octreotide",

author = "Kim, {Ju H.} and Brophy, {Donald F.} and Shah, {Keyur B.}",

year = "2018",

month = nov,

day = "1",

doi = "10.1016/j.ccl.2018.06.006",

language = "English (US)",

volume = "36",

pages = "519--529",

journal = "Cardiology Clinics",

issn = "0733-8651",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding

AU - Kim, Ju H.

AU - Brophy, Donald F.

AU - Shah, Keyur B.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Continuous-flow (CF) left ventricular assist devices (LVADs) are a safe and durable therapeutic option for patients with advanced heart failure as a bridge to transplant or as destination therapy. Despite the remarkable technological advances in device design and increasing familiarity with the physiologic effects of CF, major complications such as gastrointestinal bleeding (GIB) continue to cause significant morbidity. The causes underlying CF-LVAD–related GIB are multifactorial. Accordingly, management strategies for CF-LVAD–related GIB encompass a wide range of therapeutic modalities. This article reviews the epidemiology, pathophysiology, risk factors, and treatment options for the management of this complex complication.

AB - Continuous-flow (CF) left ventricular assist devices (LVADs) are a safe and durable therapeutic option for patients with advanced heart failure as a bridge to transplant or as destination therapy. Despite the remarkable technological advances in device design and increasing familiarity with the physiologic effects of CF, major complications such as gastrointestinal bleeding (GIB) continue to cause significant morbidity. The causes underlying CF-LVAD–related GIB are multifactorial. Accordingly, management strategies for CF-LVAD–related GIB encompass a wide range of therapeutic modalities. This article reviews the epidemiology, pathophysiology, risk factors, and treatment options for the management of this complex complication.

KW - Angiodysplasia

KW - Gastrointestinal bleed

KW - Left ventricular assist device

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=85054309995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054309995&partnerID=8YFLogxK

U2 - 10.1016/j.ccl.2018.06.006

DO - 10.1016/j.ccl.2018.06.006

M3 - Review article

C2 - 30297069

AN - SCOPUS:85054309995

VL - 36

SP - 519

EP - 529

JO - Cardiology Clinics

JF - Cardiology Clinics

SN - 0733-8651

IS - 4

ER -